Marcos F. Fondevila
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Marcos F. Fondevila has a total of 210 co-authors. Here are the top co-authors by number of shared publications:
- Natália da Silva Lima
Department of Physiology, CIMUS, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain
8 shared publications - Ruben Nogueiras
Universidade de Santiago de Compostela-Instituto de Investigation Sanitaria, Santiago de Compostela, Spain
8 shared publications Ana Senra
Department of Physiology, CiMUS, University of Santiago de Compostela, Santiago de Compostela, 15782, Spain
7 shared publicationsCarlos Dieguez
Department of Physiology, CiMUS, University of Santiago de Compostela, Santiago de Compostela, 15782, Spain
6 shared publicationsEva Novoa
Department of Physiology, CIMUS, University of Santiago de Compostela, Santiago de Compostela, 15782, Spain; CIBER Fisiopatologia de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela, 15782, Spain
6 shared publications- Miguel López
Department of Physiology, CIMUS, University of Santiago de Compostela, Santiago de Compostela, Spain
6 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by Springer Nature in Nature Metabolism
- p. 1-12
Senolytics dasatinib and quercetin in metabolic dysfunction-associated steatohepatitis: a proof-of-principle randomized, controlled trial
Cellular senescence plays an important role in hepatic inflammation and fibrosis1,2,3. However, whether senescence represents a potential therapeutic target in humans with metabolic dysfunction-associated steatohepatitis (MASH) remains unexplored. Here we report the results of a phase-2, double-blind, randomized, placebo-controlled trial of intermittent senolytic therapy with dasatinib plus quercetin (D + Q) in participants with fibrotic MASH. Thirty-one participants (median age 56 years; 76% male; 58% with type 2 diabetes) were randomized (1:1) to receive D + Q (dasatinib 100 mg per day plus quercetin 1,000 mg per day) or placebo for three consecutive days per week over 3 weeks, repeated across three 7-week cycles. The primary endpoint, ≥1 stage fibrosis improvement without MASH worsening on paired liver biopsies, is achieved in 47% of D + Q-treated participants versus 7% with placebo (P = 0.02). MASH resolution occurs more frequently with D + Q than placebo (53% versus 7%; P = 0.02), with a greater reduction in NAFLD Activity Score (−1.43 ± 1.22 versus −0.39 ± 0.77; P = 0.012). Single-nucleus RNA sequencing demonstrates decreased senescence and fibrotic gene signatures and reduced fibrogenic cell populations in the D + Q group. Although adverse events are more frequent in the D + Q group (82% versus 43%), these are all self-limiting. Overall, this proof-of-principle trial supports the need for future trials of senolytic therapy in fibrotic MASH. ClinicalTrials.gov identifier: NCT05506488.
- 1 October 2026
- Published by Springer Nature in Nature Metabolism
- p. 1-12
Open AccessSenolytics dasatinib and quercetin in metabolic dysfunction-associated steatohepatitis: a proof-of-principle randomized, controlled trial
Cellular senescence plays an important role in hepatic inflammation and fibrosis1,2,3. However, whether senescence represents a potential therapeutic target in humans with metabolic dysfunction-associated steatohepatitis (MASH) remains unexplored. Here we report the results of a phase-2, double-blind, randomized, placebo-controlled trial of intermittent senolytic therapy with dasatinib plus quercetin (D + Q) in participants with fibrotic MASH. Thirty-one participants (median age 56 years; 76% male; 58% with type 2 diabetes) were randomized (1:1) to receive D + Q (dasatinib 100 mg per day plus quercetin 1,000 mg per day) or placebo for three consecutive days per week over 3 weeks, repeated across three 7-week cycles. The primary endpoint, ≥1 stage fibrosis improvement without MASH worsening on paired liver biopsies, is achieved in 47% of D + Q-treated participants versus 7% with placebo (P = 0.02). MASH resolution occurs more frequently with D + Q than placebo (53% versus 7%; P = 0.02), with a greater reduction in NAFLD Activity Score (−1.43 ± 1.22 versus −0.39 ± 0.77; P = 0.012). Single-nucleus RNA sequencing demonstrates decreased senescence and fibrotic gene signatures and reduced fibrogenic cell populations in the D + Q group. Although adverse events are more frequent in the D + Q group (82% versus 43%), these are all self-limiting. Overall, this proof-of-principle trial supports the need for future trials of senolytic therapy in fibrotic MASH. ClinicalTrials.gov identifier: NCT05506488.
- 7 May 2026
- Published by Wiley in Liver International
- Vol. 46 (6) , e70663
Faecal Cathepsin B and S Are Associated With Liver Disease Severity and Adiposity in MASLD
Background & Aims: Dysregulation of hepatic cathepsins contributes to metabolic dysfunction‐associated steatotic liver disease (MASLD) by promoting inflammation, apoptosis, and fibrosis. However, the role of intestinal cathepsins in MASLD has not been investigated. Given the central role of the gut‐liver axis in disease progression, this represents an important knowledge gap. Methods: Faecal cathepsin B and S activity was measured in 95 patients with MASLD and 18 healthy controls. Cathepsin activity was correlated with liver disease severity, metabolic parameters, and gut microbiome composition. Results: Faecal cathepsin B and S activity was higher in patients with MASLD than in healthy controls. Cathepsin B activity was further increased in patients with metabolic dysfunction‐associated steatohepatitis. Cathepsin B and S activity correlated with serum transaminases and hepatic steatosis, while cathepsin B activity was additionally associated with liver stiffness. Cathepsin B and S activity correlated with adiposity but showed no associations with other metabolic dysfunction‐related parameters. Moreover, gut microbiome composition differed between patients with low vs. high faecal cathepsin B or S activity, respectively. Conclusion: Increased faecal cathepsin B and S activity is associated with liver disease severity and adiposity in MASLD and is linked to alterations of the gut microbiome, suggesting a potential role of intestinal cathepsins in gut‐liver axis dysfunction.
- 7 May 2026
- Published by Wiley in Liver International
- Vol. 46 (6) , e70663
Faecal Cathepsin B and S Are Associated With Liver Disease Severity and Adiposity in MASLD
Background & Aims: Dysregulation of hepatic cathepsins contributes to metabolic dysfunction‐associated steatotic liver disease (MASLD) by promoting inflammation, apoptosis, and fibrosis. However, the role of intestinal cathepsins in MASLD has not been investigated. Given the central role of the gut‐liver axis in disease progression, this represents an important knowledge gap. Methods: Faecal cathepsin B and S activity was measured in 95 patients with MASLD and 18 healthy controls. Cathepsin activity was correlated with liver disease severity, metabolic parameters, and gut microbiome composition. Results: Faecal cathepsin B and S activity was higher in patients with MASLD than in healthy controls. Cathepsin B activity was further increased in patients with metabolic dysfunction‐associated steatohepatitis. Cathepsin B and S activity correlated with serum transaminases and hepatic steatosis, while cathepsin B activity was additionally associated with liver stiffness. Cathepsin B and S activity correlated with adiposity but showed no associations with other metabolic dysfunction‐related parameters. Moreover, gut microbiome composition differed between patients with low vs. high faecal cathepsin B or S activity, respectively. Conclusion: Increased faecal cathepsin B and S activity is associated with liver disease severity and adiposity in MASLD and is linked to alterations of the gut microbiome, suggesting a potential role of intestinal cathepsins in gut‐liver axis dysfunction.
- 29 April 2026
- Published by Elsevier in Journal of Hepatology
- Vol. 85 (2) , e53-e54
Reply to: “Hepatic CTSB is Kupffer cell-enriched, whereas disease-state stratification is more strongly captured by endotoxin/TLR4 programmes”
- 29 April 2026
- Published by Elsevier in Journal of Hepatology
- Vol. 85 (2) , e53-e54
Reply to: “Hepatic CTSB is Kupffer cell-enriched, whereas disease-state stratification is more strongly captured by endotoxin/TLR4 programmes”
- 6 February 2026
- Published by Elsevier in Journal of Hepatology
- Vol. 84 (6) , 1045-1061
Macrophage-derived cathepsin B disrupts intestinal tight junctions through occludin degradation and promotes alcohol-associated liver disease
- 6 February 2026
- Published by Elsevier in Journal of Hepatology
- Vol. 84 (6) , 1045-1061
Macrophage-derived cathepsin B disrupts intestinal tight junctions through occludin degradation and promotes alcohol-associated liver disease
- Open Access
- 29 May 2024
- Published by Elsevier in Molecular Metabolism
- Vol. 85, 101962
Inhibition of hepatic p63 ameliorates steatohepatitis with fibrosis in mice
- 29 May 2024
- Published by Elsevier in Molecular Metabolism
- Vol. 85, 101962
Open AccessInhibition of hepatic p63 ameliorates steatohepatitis with fibrosis in mice
- Open Access
- 16 May 2024
- Published by Wolters Kluwer Health in Hepatology
- Vol. 81 (5) , 1535-1552
Mitochondrial antiviral signaling protein enhances MASLD progression through the ERK/TNFα/NFκβ pathway
Background and Aims: Mitochondrial antiviral signaling protein (MAVS) is a critical regulator that activates the host’s innate immunity against RNA viruses, and its signaling pathway has been linked to the secretion of proinflammatory cytokines. However, the actions of MAVS on inflammatory pathways during the development of metabolic dysfunction–associated steatotic liver disease (MASLD) have been little studied. Approach and Results: Liver proteomic analysis of mice with genetically manipulated hepatic p63, a transcription factor that induces liver steatosis, revealed MAVS as a target downstream of p63. MAVS was thus further evaluated in liver samples from patients and in animal models with MASLD. Genetic inhibition of MAVS was performed in hepatocyte cell lines, primary hepatocytes, spheroids, and mice. MAVS expression is induced in the liver of both animal models and people with MASLD as compared with those without liver disease. Using genetic knockdown of MAVS in adult mice ameliorates diet-induced MASLD. In vitro, silencing MAVS blunts oleic and palmitic acid–induced lipid content, while its overexpression increases the lipid load in hepatocytes. Inhibiting hepatic MAVS reduces circulating levels of the proinflammatory cytokine TNFα and the hepatic expression of both TNFα and NFκβ. Moreover, the inhibition of ERK abolished the activation of TNFα induced by MAVS. The posttranslational modification O-GlcNAcylation of MAVS is required to activate inflammation and to promote the high lipid content in hepatocytes. Conclusions: MAVS is involved in the development of steatosis, and its inhibition in previously damaged hepatocytes can ameliorate MASLD.
- 16 May 2024
- Published by Wolters Kluwer Health in Hepatology
- Vol. 81 (5) , 1535-1552
Open AccessMitochondrial antiviral signaling protein enhances MASLD progression through the ERK/TNFα/NFκβ pathway
Background and Aims: Mitochondrial antiviral signaling protein (MAVS) is a critical regulator that activates the host’s innate immunity against RNA viruses, and its signaling pathway has been linked to the secretion of proinflammatory cytokines. However, the actions of MAVS on inflammatory pathways during the development of metabolic dysfunction–associated steatotic liver disease (MASLD) have been little studied. Approach and Results: Liver proteomic analysis of mice with genetically manipulated hepatic p63, a transcription factor that induces liver steatosis, revealed MAVS as a target downstream of p63. MAVS was thus further evaluated in liver samples from patients and in animal models with MASLD. Genetic inhibition of MAVS was performed in hepatocyte cell lines, primary hepatocytes, spheroids, and mice. MAVS expression is induced in the liver of both animal models and people with MASLD as compared with those without liver disease. Using genetic knockdown of MAVS in adult mice ameliorates diet-induced MASLD. In vitro, silencing MAVS blunts oleic and palmitic acid–induced lipid content, while its overexpression increases the lipid load in hepatocytes. Inhibiting hepatic MAVS reduces circulating levels of the proinflammatory cytokine TNFα and the hepatic expression of both TNFα and NFκβ. Moreover, the inhibition of ERK abolished the activation of TNFα induced by MAVS. The posttranslational modification O-GlcNAcylation of MAVS is required to activate inflammation and to promote the high lipid content in hepatocytes. Conclusions: MAVS is involved in the development of steatosis, and its inhibition in previously damaged hepatocytes can ameliorate MASLD.
- Open Access
- 9 February 2024
- Published by Elsevier in Cell Reports Medicine
- Vol. 5 (2) , 101401
p63 controls metabolic activation of hepatic stellate cells and fibrosis via an HER2-ACC1 pathway
- 9 February 2024
- Published by Elsevier in Cell Reports Medicine
- Vol. 5 (2) , 101401
Open Accessp63 controls metabolic activation of hepatic stellate cells and fibrosis via an HER2-ACC1 pathway
- Open Access
Hepatic p63 regulates glucose metabolism by repressing SIRT1
Objective p63 is a transcription factor within the p53 protein family that has key roles in development, differentiation and prevention of senescence, but its metabolic actions remain largely unknown. Herein, we investigated the physiological role of p63 in glucose metabolism. Design We used cell lines and mouse models to genetically manipulate p63 in hepatocytes. We also measured p63 in the liver of patients with obesity with or without type 2 diabetes (T2D). Results We show that hepatic p63 expression is reduced on fasting. Mice lacking the specific isoform TAp63 in the liver (p63LKO) display higher postprandial and pyruvate-induced glucose excursions. These mice have elevated SIRT1 levels, while SIRT1 knockdown in p63LKO mice normalises glycaemia. Overexpression of TAp63 in wild-type mice reduces postprandial, pyruvate-induced blood glucose and SIRT1 levels. Studies carried out in hepatocyte cell lines show that TAp63 regulates SIRT1 promoter by repressing its transcriptional activation. TAp63 also mediates the inhibitory effect of insulin on hepatic glucose production, as silencing TAp63 impairs insulin sensitivity. Finally, protein levels of TAp63 are reduced in obese persons with T2D and are negatively correlated with fasting glucose and homeostasis model assessment index. Conclusions. These results demonstrate that p63 physiologically regulates glucose homeostasis.
Open AccessHepatic p63 regulates glucose metabolism by repressing SIRT1
Objective p63 is a transcription factor within the p53 protein family that has key roles in development, differentiation and prevention of senescence, but its metabolic actions remain largely unknown. Herein, we investigated the physiological role of p63 in glucose metabolism. Design We used cell lines and mouse models to genetically manipulate p63 in hepatocytes. We also measured p63 in the liver of patients with obesity with or without type 2 diabetes (T2D). Results We show that hepatic p63 expression is reduced on fasting. Mice lacking the specific isoform TAp63 in the liver (p63LKO) display higher postprandial and pyruvate-induced glucose excursions. These mice have elevated SIRT1 levels, while SIRT1 knockdown in p63LKO mice normalises glycaemia. Overexpression of TAp63 in wild-type mice reduces postprandial, pyruvate-induced blood glucose and SIRT1 levels. Studies carried out in hepatocyte cell lines show that TAp63 regulates SIRT1 promoter by repressing its transcriptional activation. TAp63 also mediates the inhibitory effect of insulin on hepatic glucose production, as silencing TAp63 impairs insulin sensitivity. Finally, protein levels of TAp63 are reduced in obese persons with T2D and are negatively correlated with fasting glucose and homeostasis model assessment index. Conclusions. These results demonstrate that p63 physiologically regulates glucose homeostasis.
- Open Access
- 12 February 2022
- Published by Elsevier in Journal of Hepatology
- Vol. 77 (1) , 15-28
Inhibition of carnitine palmitoyltransferase 1A in hepatic stellate cells protects against fibrosis
- 12 February 2022
- Published by Elsevier in Journal of Hepatology
- Vol. 77 (1) , 15-28
Open AccessInhibition of carnitine palmitoyltransferase 1A in hepatic stellate cells protects against fibrosis
- Open Access
- 1 January 2022
- Published by Elsevier in Journal of Hepatology
- Vol. 76 (1) , 11-24
Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function
- 1 January 2022
- Published by Elsevier in Journal of Hepatology
- Vol. 76 (1) , 11-24
Open AccessInhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function